PipelineReview.com9h
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
REYKJAVIK, Iceland and PARSIPPANY, NJ, USA I1, 2025 I Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: ...
PipelineReview.com8h
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
INGELHEIM, Germany I, 2025 I Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)∗ and OXB,ŧ today announce the start ...
PipelineReview.com8h
Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort
EMERYVILLE, CA, USA I1, 2025 I Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical stage biopharmaceutical ...
PipelineReview.com8h
Myris Therapeutics is Developing Ultra-High DAR ADCs to Enable Novel Precision Medicine Treatments for Cancer
PITTSBURGH, PA, USA I February 20, 2025 I Myris Therapeutics™ emerged from stealth today to announce its strategic focus. Myris, formerly known as ...
PipelineReview.com8h
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Approved, Seladelpar Can Provide an Important Treatment Option for People Living With the Rare Liver Disease in the European Economic Area – ...
PipelineReview.com8h
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
bluebird stockholders to receive $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales ...
PipelineReview.com9h
NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program
NKGen takes a meaningful step towards potential treatment for frontotemporal dementia (“FTD”) patients with limited treatment options.